Nasus Pharma Ltd is a clinical stage pharmaceutical company developing innovative intranasal products to treat emergency medical conditions. The company operates as a virtual entity with its headquarters in Tel Aviv Israel. Its mission is to provide better protection for patients during acute severe and life threatening conditions through effective user friendly and immediately active powder based formulations. The lead development programs are NS002 an intranasal epinephrine powder aimed at allergic reactions and anaphylactic shock and NS001 an intranasal naloxone powder aimed at opioid overdose. In addition the company is pursuing preclinical programs for nasally delivered midazolam for seizures atropine for organophosphate poisoning and ondansetron for nausea and vomiting. Nasus Pharma Ltd relies on its proprietary powder technology which creates uniform spherical particles designed to increase nasal absorption area and improve drug delivery speed. The technology has been tested in multiple clinical studies demonstrating faster absorption compared to standard injectable products and has shown stability without the degradation issues seen in liquid formulations.

Nasus Pharma Ltd currently generates no revenue from product sales as it remains in the pre commercial stage focusing on advancing its pipeline candidates toward regulatory approval. The company has not yet launched any FDA approved products and therefore does not have product sales or service income. Its financial resources come primarily from external financing including equity offerings and loans to fund research development clinical trials and manufacturing scale up activities. Management expects that revenue will begin only after successful regulatory clearance and commercial launch of its lead products. The company plans to submit an investigational new drug application for NS002 in the third quarter of 2026 followed by a pivotal phase 3 study in the fourth quarter of 2026 with a view to file a new drug application by the second half of 2027. Similar timelines are envisaged for NS001 although development of that candidate has been paused to seek partnership opportunities. In parallel Nasus Pharma Ltd is advancing its preclinical candidates toward first in human studies expected to start in the second half of 2026.

The intranasal drug delivery market is large with the United States segment valued at about $22 billion in 2021 representing roughly 40% of the global market. China is expected to reach a $5.7 billion market by 2026 while the global market was $59 billion in 2022 and is forecast to grow at 6.9% CAGR to $93.7 billion by 2029. Within the epinephrine segment the global market was valued at $2.3 billion in 2024 and is expected to expand to $4.4 billion by 2032 driven by increasing demand for allergy treatments. The naloxone segment is also expanding with forecasts suggesting the market could reach $785 million by 2025 at a compound annual growth rate of 22.3%. Nasus Pharma Ltd competes against established products such as Mylan's EpiPen for epinephrine and Adapt Pharma's Narcan for naloxone. Additional competitors include ARS Pharmaceuticals' Neffy Bryn Pharma's intranasal epinephrine Orexo's formulation and Aquestive's sublingual film for epinephrine as well as Hikma's Kloxxado for naloxone. The company's competitive advantage lies in its proprietary powder based technology which creates a larger nasal absorption area compared to liquid sprays provides rapid and stable drug delivery and eliminates the need for needles. This technology has shown in early clinical studies faster achievement of therapeutic plasma levels than the reference autoinjectors while maintaining a comparable safety profile.

The company intends to serve patients who experience sudden allergic reactions or opioid overdose and require rapid intervention. This includes individuals who self administer medication as well as healthcare professionals such as paramedics emergency physicians and hospital staff who treat acute cases in outpatient and inpatient settings. Additionally public health agencies and emergency response organizations may become customers for stockpiling the products. Nasus Pharma Ltd anticipates that its products will be distributed through retail pharmacies hospital formularies and wholesale distributors once they receive regulatory approval. The company also expects to enter into partnership agreements with larger pharmaceutical firms to leverage their sales and marketing networks for broader market reach. No specific customer names are disclosed in the filing because the company remains pre revenue and has not yet entered into commercial supply agreements.